Clinical Trials in Systemic Sclerosis: Crossroads and Opportunities

Affiliations

Editorial

Laura K Hummers. Arthritis Rheumatol. 2023 Aug.

. 2023 Aug;75(8):1328-1330.

doi: 10.1002/art.42514. Epub 2023 Jun 23.

No abstract available

Comment on

A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.
Khanna D, Denton CP, Furst DE, Mayes MD, Matucci-Cerinic M, Smith V, de Vries D, Ford P, Bauer Y, Randall MJ, Ebrahimpoor M, Kupcsik L, Stiers PJ, Deberdt L, Prasad N, Lim S, Pujuguet P, Ahmed S. Khanna D, et al. Arthritis Rheumatol. 2023 Aug;75(8):1434-1444. doi: 10.1002/art.42477. Epub 2023 May 15. Arthritis Rheumatol. 2023. PMID: 36787101 Clinical Trial.

1. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019;380:2518-28.
1. Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial [published corrections appear in Lancet Respir Med 2020;8:e75 and Lancet Respir Med 2021;9:e29]. Lancet Respir Med 2020;8:963-74.
1. Khanna D, Berrocal VJ, Giannini EH, et al. The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 2016;68:299-311.
1. Khanna D, Huang S, Lin CJF, et al. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis [published correction appears in Ann Rheum Dis 2021;80:e154]. Ann Rheum Dis 2021;80:641-50.
1. Allanore Y, Distler O, Jagerschmidt A, et al. Lysophosphatidic acid receptor 1 antagonist SAR100842 for patients with diffuse cutaneous systemic sclerosis: a double-blind, randomized, eight-week placebo-controlled study followed by a sixteen-week open-label extension study. Arthritis Rheumatol 2018;70:1634-43.